One of the world's leading COVID-19 experimental vaccines produces an immune response in both young and old adults, raising hopes of a path out of the pessimism and economic destruction bent by the novel coronavirus. The COVID-19 vaccine developed by the University of Oxford produces an immune response in the elderly and young and the side effects were frailer in the elderly, British drug maker AstraZeneca Plc said on Monday.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman said in a media interview.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the vaccine. The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate, as the world tries to plot a path out of the COVID-19 pandemic.
AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets nearer to reporting early results of a late-stage clinical trial. It resumed the U.S. trial of the experimental vaccine after approval by U.S. regulators.
Well, we can’t be more than happy to know about the success of the vaccine trial. We are awaiting for the vaccine to go public.